Evidence map›Paper›PMID 41161754›Full record

ArticleEnvironmental health and preventive medicine2025

Anti-early antigen Epstein-Barr virus titer and atherosclerosis in relation to vascular endothelial growth factor (VEGF) polymorphism rs3025039 among older Japanese individuals.

Yuji Shimizu, Hirotomo Yamanashi, Shin-Ya Kawashiri, Yuko Noguchi, Nagisa Sasaki, Seiko Nakamichi, Kazuhiko Arima, Yasuhiro Nagata, Takahiro Maeda

Abstract read
In one paragraph

Article in Environmental health and preventive medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Yuji ShimizuEpidemiology Section, Division of Public Health, Osaka Institute of Public Health.ORCID http://orcid.org/0000-0002-3381-9288
Hirotomo YamanashiDepartment of General Medicine, Nagasaki University Graduate School of Biomedical Sciences.ORCID http://orcid.org/0000-0002-8655-4519
Shin-Ya KawashiriLeading Medical Research Core Unit, Nagasaki University Graduate School of Biomedical Sciences.ORCID http://orcid.org/0000-0002-2606-995X
Yuko NoguchiDepartment of Community Medicine, Nagasaki University Graduate School of Biomedical Sciences.
Nagisa SasakiEpidemiology Section, Division of Public Health, Osaka Institute of Public Health.
Seiko NakamichiDepartment of General Medicine, Nagasaki University Graduate School of Biomedical Sciences.ORCID http://orcid.org/0000-0002-3885-3581
Kazuhiko ArimaLeading Medical Research Core Unit, Nagasaki University Graduate School of Biomedical Sciences.ORCID http://orcid.org/0000-0003-1149-9428
Yasuhiro NagataLeading Medical Research Core Unit, Nagasaki University Graduate School of Biomedical Sciences.ORCID http://orcid.org/0000-0003-1353-7272
Takahiro MaedaDepartment of General Medicine, Nagasaki University Graduate School of Biomedical Sciences.ORCID http://orcid.org/0000-0003-4530-6460

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundEpstein-Barr (EB) virus infection stimulates the production of vascular endothelial growth factor (VEGF), which contributes to the progression of angiogenesis. Angiogenesis plays an important role in the development of atherosclerosis. Since serum anti-early antigen EB virus IgG (EBV EA-IgG) titer is a sign of active EB virus infection, EBV EA-IgG titer could be associated with atherosclerosis. The number of minor (T) alleles in VEGF polymorphism rs3025039 has been reported to be inversely associated with serum VEGF concentration, suggesting that rs3025039 might have a strong influence on the association between EBV EA-IgG titer and atherosclerosis. By focusing on the role of VEGF in the development of atherosclerosis, this study aimed to investigate the association between active EB virus infection and atherosclerosis.

methodsA cross-sectional study of 2,661 older Japanese individuals aged 60-89 years who participated in annual health check-ups during 2017-2019 was conducted. Logistic regression was used to evaluate the association between EBV EA-IgG titer and atherosclerosis in relation to rs3025039 genotype. The influence of rs3025039 (T) allele carrier status on the association between EBV EA-IgG titer and atherosclerosis was also evaluated by using logistic regression.

resultsAmong rs3025039 CC-homozygotes, with the lowest EBV EA-IgG titer tertile as the reference, the multivariable odds ratio (95% confidence interval) was 1.11 (0.82, 1.50) for the medium tertile and 1.07 (0.78, 1.47) for the high tertile. Among rs3025039 (T) allele carriers, the corresponding values were 1.44 (0.88, 2.36) and 1.88 (1.15, 3.05), respectively. There was a significant interaction between rs3025039 (T) allele carrier status and the association between EBV EA-IgG titer and atherosclerosis (adjusted p = 0.0497).

conclusionEBV EA-IgG titer was significantly positively associated with atherosclerosis only among participants who are genetically less likely to have progressive angiogenesis. An angiogenesis-related genetic factor was revealed as a determinant of the association between EBV EA-IgG titer and atherosclerosis. These findings introduce a novel concept that could explain the association between viral infection and atherosclerosis.

Indexed as

Antigens, ViralAtherosclerosisEpstein-Barr Virus InfectionsHerpesvirus 4, HumanVascular Endothelial Growth Factor AAgedAged, 80 and overAntibodies, ViralCross-Sectional StudiesEast Asian PeopleFemaleGenotypeHumansImmunoglobulin GJapanMaleAntibodies, ViralAntigens, ViralEpstein-Barr virus early antigenImmunoglobulin GVascular Endothelial Growth Factor AVEGFA protein, humanAngiogenesisAtherosclerosisEB virusrs3025039SNPVEGF

Identifiers

PMID41161754
PMCPMC12583969

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.